• 1. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 2. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 3. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 4. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 5. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471

Introduction to 3,6-dimethyl-Imidazo[1,2-a]pyridine (CAS No. 78132-62-4)

3,6-dimethyl-Imidazo[1,2-a]pyridine, identified by its Chemical Abstracts Service (CAS) number 78132-62-4, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This bicyclic structure, featuring a fused imidazole and pyridine ring system with two methyl substituents at the 3rd and 6th positions, exhibits a unique set of chemical and biological properties that make it a promising candidate for various therapeutic applications.

The molecular framework of 3,6-dimethyl-Imidazo[1,2-a]pyridine contributes to its versatility in drug design. The presence of nitrogen atoms in both the imidazole and pyridine rings allows for multiple hydrogen bonding interactions, enhancing its binding affinity to biological targets. This feature has been exploited in the development of novel compounds targeting a range of diseases, including cancer, infectious diseases, and neurological disorders.

Recent advancements in computational chemistry and molecular modeling have further illuminated the potential of 3,6-dimethyl-Imidazo[1,2-a]pyridine as a scaffold for drug discovery. Studies have demonstrated that the compound can be modified to enhance its pharmacokinetic properties, such as solubility and bioavailability. These modifications often involve the introduction of additional functional groups or the alteration of existing ones to optimize receptor binding and metabolic stability.

In the realm of oncology, 3,6-dimethyl-Imidazo[1,2-a]pyridine has been investigated for its ability to inhibit specific kinases involved in tumor growth and progression. For instance, derivatives of this compound have shown promise in targeting tyrosine kinases, which are critical in signal transduction pathways that drive cancer cell proliferation. Preclinical studies have revealed that certain analogs exhibit potent antitumor activity with acceptable toxicity profiles.

The antimicrobial potential of 3,6-dimethyl-Imidazo[1,2-a]pyridine has also been explored. Researchers have identified that modifications to the core structure can enhance activity against resistant bacterial strains. This is particularly relevant in an era where antibiotic resistance poses a growing threat to global health. By leveraging the scaffold's inherent flexibility, chemists have designed molecules capable of disrupting bacterial cell wall synthesis or interfering with essential metabolic pathways.

Neurological research has similarly benefited from the study of 3,6-dimethyl-Imidazo[1,2-a]pyridine. Its ability to cross the blood-brain barrier has made it a valuable starting point for developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. Initial studies suggest that certain derivatives can modulate neurotransmitter release and protect against oxidative stress-induced neuronal damage.

The synthesis of 3,6-dimethyl-Imidazo[1,2-a]pyridine involves multi-step organic reactions that highlight the compound's synthetic accessibility. Common synthetic routes include cyclization reactions followed by functional group interconversions. Advances in green chemistry have also led to more sustainable methods for producing this compound, reducing waste and minimizing hazardous byproducts.

From a regulatory perspective, 3,6-dimethyl-Imidazo[1,2-a]pyridine (CAS No. 78132-62-4) is subject to standard pharmaceutical guidelines ensuring its safe handling and use in research settings. Compliance with Good Manufacturing Practices (GMP) is crucial when scaling up production for clinical trials or commercialization.

The future prospects for 3,6-dimethyl-Imidazo[1,2-a]pyridine are promising, with ongoing research aimed at expanding its therapeutic applications. Collaborative efforts between academic institutions and pharmaceutical companies are likely to yield innovative derivatives with improved efficacy and safety profiles. As our understanding of biological pathways continues to evolve, so too will the potential uses for this versatile heterocyclic compound.

• 1010698-75-5(6-ethynyl-2-methyl-Imidazo[1,2-a]pyridine)
• 1238291-40-1(3,6-dimethyl-Imidazo[2,1-a]isoquinoline)
• 1216132-36-3((3-Methylimidazo1,2-apyridin-6-yl)methanamine Dihydrochloride)
• 3268-61-9(2,7-dimethylimidazo1,2-apyridine)
• 934-37-2(2-Methylimidazo[1,2-A]pyridine)
• 34165-19-0(Imidazo[1,2-a]pyridine,2,3,5-trimethyl-)
• 1238291-63-8(3,8-dimethyl-Imidazo[2,1-a]isoquinoline)
• 5857-45-4(3-Methylimidazo1,2-apyridine)
• 102308-96-3(2,6-dimethyl-imidazo[1,2-a]pyridine)
• 6188-30-3(2,5-dimethylimidazo1,2-apyridine)